234 related articles for article (PubMed ID: 16415430)
1. Hürthle cell tumors: applying molecular markers to define a new management algorithm.
Maxwell EL; Palme CE; Freeman J
Arch Otolaryngol Head Neck Surg; 2006 Jan; 132(1):54-8. PubMed ID: 16415430
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
[TBL] [Abstract][Full Text] [Related]
3. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
4. Unilateral lobectomy for Hurthle cell adenoma.
Wasvary H; Czako P; Poulik J; Lucas R
Am Surg; 1998 Aug; 64(8):729-32; discussion 732-3. PubMed ID: 9697901
[TBL] [Abstract][Full Text] [Related]
5. Hurthle cell neoplasm of the thyroid gland.
Ahmed M; Bin Yousef H; Greer W; Faraz H; Al Sobhi S; Al Zahrani A; Raef H; Al Ghamdi A; Al Kadhi Y; Al Dayel F
ANZ J Surg; 2008 Mar; 78(3):139-43. PubMed ID: 18269475
[TBL] [Abstract][Full Text] [Related]
6. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions.
Chiappetta G; Toti P; Cetta F; Giuliano A; Pentimalli F; Amendola I; Lazzi S; Monaco M; Mazzuchelli L; Tosi P; Santoro M; Fusco A
J Clin Endocrinol Metab; 2002 Jan; 87(1):364-9. PubMed ID: 11788677
[TBL] [Abstract][Full Text] [Related]
7. Hybrid thyroid carcinoma with a coarse chromatin pattern and nuclear features of papillary thyroid carcinoma.
Mai KT; Bokhary R; Yazdi HM; Thomas J
Pathol Res Pract; 2002; 198(4):253-60. PubMed ID: 12049333
[TBL] [Abstract][Full Text] [Related]
8. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
9. Hurthle cell tumor.
Chen HY; Benjamin LB; Chen MF
Int Surg; 1996; 81(2):168-70. PubMed ID: 8912085
[TBL] [Abstract][Full Text] [Related]
10. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
11. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
12. RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hürthle cell carcinomas?
Musholt PB; Imkamp F; von Wasielewski R; Schmid KW; Musholt TJ
Surgery; 2003 Dec; 134(6):881-9; discussion 889. PubMed ID: 14668719
[TBL] [Abstract][Full Text] [Related]
13. Hürthle cell tumors: a twenty-five-year experience.
Arganini M; Behar R; Wu TC; Straus F; McCormick M; DeGroot LJ; Kaplan EL
Surgery; 1986 Dec; 100(6):1108-15. PubMed ID: 3787466
[TBL] [Abstract][Full Text] [Related]
14. Influence of previous radiation exposure on pathologic features and clinical outcome in patients with thyroid cancer.
Seaberg RM; Eski S; Freeman JL
Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):355-9. PubMed ID: 19380356
[TBL] [Abstract][Full Text] [Related]
15. [Clinical experience in Hurthle cell tumors].
Francomano F; Napolitano L; Scipione P; Savini F; Bajocchi G; Angelucci D
G Chir; 1998; 19(11-12):449-52. PubMed ID: 9882947
[TBL] [Abstract][Full Text] [Related]
16. Favorable Outcome of Hurthle Cell Carcinoma of the Thyroid Treated With Total Thyroidectomy, Radioiodine, and Selective Use of External-Beam Radiotherapy.
Zavitsanos P; Amdur RJ; Drew PA; Cusi K; Werning JW; Morris CG
Am J Clin Oncol; 2017 Aug; 40(4):433-437. PubMed ID: 25730603
[TBL] [Abstract][Full Text] [Related]
17. Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma.
Mai KT; Khanna P; Yazdi HM; Perkins DG; Veinot JP; Thomas J; Lamba M; Nair BD
Pathology; 2002 Jun; 34(3):239-44. PubMed ID: 12109784
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
19. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid.
Erickson LA; Jin L; Goellner JR; Lohse C; Pankratz VS; Zukerberg LR; Thompson GB; van Heerden JA; Grant CS; Lloyd RV
Mod Pathol; 2000 Feb; 13(2):186-92. PubMed ID: 10697277
[TBL] [Abstract][Full Text] [Related]
20. [Multifocal papillary thyroid carcinoma: clinical analysis of 168 cases].
Lin YK; Sheng JM; Zhao WH; Wang WB; Yu XF; Teng LS; Ma ZM
Zhonghua Wai Ke Za Zhi; 2009 Mar; 47(6):450-3. PubMed ID: 19595234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
